Sen. Cory A. Booker Sells Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Senator Cory A. Booker (Democratic-New Jersey) recently sold shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). In a filing disclosed on September 09th, the Senator disclosed that they had sold between $1,001 and $15,000 in Alnylam Pharmaceuticals stock on August 11th.

Senator Cory A. Booker also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 8/11/2026.
• Sold $15,001 – $50,000 in shares of McDonald’s (NYSE:MCD) on 8/11/2026.
• Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/11/2026.
• Sold $1,001 – $15,000 in shares of JD.com (NASDAQ:JD) on 8/11/2026.
• Sold $100,001 – $250,000 in shares of Amazon.com (NASDAQ:AMZN) on 8/11/2026.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY traded up $1.17 during trading hours on Friday, hitting $248.68. The company’s stock had a trading volume of 1,177,278 shares, compared to its average volume of 1,659,503. The business’s 50-day moving average is $254.43 and its two-hundred day moving average is $288.99. The company has a market capitalization of $33.28 billion, a PE ratio of 46.22 and a beta of 0.31. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter last year, the company earned ($0.51) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 66.9% compared to the same quarter last year. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ALNY has been the subject of several recent analyst reports. Sanford C. Bernstein reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, July 31st. HC Wainwright reaffirmed a “buy” rating and issued a $455.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 2nd. Stifel Nicolaus reduced their price target on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Finally, Royal Bank Of Canada decreased their price target on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $376.67.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. Daiwa Securities Group Inc. raised its position in Alnylam Pharmaceuticals by 0.3% during the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after acquiring an additional 35 shares during the last quarter. Golden State Wealth Management LLC grew its position in shares of Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Coldstream Capital Management Inc. grew its position in shares of Alnylam Pharmaceuticals by 2.4% in the third quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $748,000 after purchasing an additional 38 shares during the last quarter. Atlantic Union Bankshares Corp increased its stake in shares of Alnylam Pharmaceuticals by 20.9% during the 4th quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company’s stock worth $92,000 after purchasing an additional 40 shares in the last quarter. Finally, Laird Norton Wetherby Wealth Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 3.3% during the 3rd quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,266 shares of the biopharmaceutical company’s stock worth $577,000 after purchasing an additional 40 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

About Senator Booker

Cory Booker (Democratic Party) is a member of the U.S. Senate from New Jersey. He assumed office on October 31, 2013. His current term ends on January 3, 2027. Booker (Democratic Party) ran for re-election to the U.S. Senate to represent New Jersey. He won in the general election on November 3, 2020. Booker also ran for election for President of the United States. He did not appear on the ballot for the Democratic convention on August 18, 2020. Booker announced that he was running for president of the United States on February 1, 2019. He suspended his presidential campaign on January 13, 2020. Before being elected to the Senate, Booker served as the 36th mayor of Newark. He also served on the Newark City Council for the Central Ward. In September 2017, he was rated the third most liberal senator based on his voting record, according to The New York Times. Booker was born in 1969 in Washington, D.C., and grew up in Harrington Park, New Jersey. He attended Stanford University on a varsity football scholarship, receiving a B.A. in 1991 and an M.A. in 1992. Booker was a Rhodes Scholar at the University of Oxford, where he earned a graduate degree in history in 1994. He then attended Yale Law School, graduating with a J.D. in 1997. After completing his education, Booker moved into a public housing project in Newark, New Jersey, became a tenant organizer, and founded a nonprofit that provided legal assistance to low-income families. He was elected to the Newark City Council in 1998 and served there until 2002, when he ran unsuccessfully for mayor. The same year, he became a partner at Booker, Rabinowitz, Trenk, Lubetkin, Tully, DiPasquale & Webster. In 2006, Booker ran again for mayor of Newark and was elected with 72% of the vote. He served as mayor until 2013. On October 16, 2013, Booker won a special election to the U.S. Senate after the death of Sen. Frank Lautenberg (D). Booker was re-elected to the U.S. Senate on November 4, 2014. In 2016, Booker published a memoir titled United: Thoughts on Finding Common Ground and Advancing the Common Good.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).